>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息：
肺心病患者血清SCUBE1、CTRP5水平与病情发展及预后的相关性分析
作者：刘贵烊  陈桂良  孟宇  唐大东 
单位：阿坝藏族羌族自治州人民医院 内三科, 四川 阿坝藏族羌族自治州 624000
关键词：肺心病 血清信号肽-CUB-表皮生长因子结构域包含蛋白1 补体C1q肿瘤坏死因子相关蛋白5 病情发展 预后 相关性 
分类号：R541.5;R446
出版年·卷·期（页码）：2024·43·第六期（911-917）
摘要：

目的:探讨肺心病患者血清信号肽-CUB-表皮生长因子结构域包含蛋白1(SCUBE1)、补体C1q肿瘤坏死因子相关蛋白5(CTRP5)水平与患者病情发展及预后的相关性。方法:选取2020年1月至2023年1月于本院就诊的160例肺心病患者,根据患者病情严重程度分为代偿组(n=80)和失代偿组(n=80);根据患者预后情况分为预后不良组(n=55)和预后良好组(n=105)。另选取同期来我院体检的健康者160例作为对照组。采用酶联免疫法检测受试者血清SCUBE1、CTRP5表达水平,比较分析各组血清SCUBE1、CTRP5表达水平差异;Logistic回归分析肺心病患者预后不良的影响因素,受试者工作特征(ROC)曲线分析SCUBE1、CTRP5水平对肺心病患者预后不良的预测价值。结果:肺心病组血清SCUBE1、CTRP5水平均显著高于对照组(P＜0.05);代偿组血清SCUBE1、CTRP5水平均显著低于失代偿组(P＜0.05);预后不良组有吸烟史占比、血清SCUBE1和CTRP5水平显著高于预后良好组(P＜0.05);吸烟史、血清SCUBE1和CTRP5是引发肺心病患者预后不良的危险因素(P＜0.05);血清SCUBE1、CTRP5联合预测肺心病患者预后不良的效能显著高于二者单独预测(ZSCUBE1-联合=3.765,P＜0.001;ZCTRP5-联合=2.067,P=0.039)。结论:肺心病患者血清SCUBE1、CTRP5水平与病情发展及预后密切相关,且二者联合对患者预后具有较高的预测价值。

Objective: To investigate the correlation between the levels of serum signal peptide-CUB-epidermal growth factor-like domain-containing protein 1(SCUBE1), complement C1q tumor necrosis factor related protein 5(CTRP5) and progression, prognosis of disease. Methods: 160 patients with pulmonary heart disease who visited our hospital from January 2020 to January 2023 were selected. According to the severity of the patient's condition, they were divided into a compensated group(n=80) and a decompensated group(n=80); according to the patient's prognosis, they were separated into a poor prognosis group(n=55) and a good prognosis group(n=105).Another 160 healthy individuals who came to our hospital for physical examination were regarded as the control group. The SCUBE1 and CTRP5 expression levels in serum of subjects were detected by ELISA method. The differences of serum SCUBE1 and CTRP5 expression levels were compared and analyzed among different groups. Logistic regression was applied to analyze the influencing factors of poor prognosis in patients with pulmonary heart disease, and ROC curve was applied to analyze the predictive value of SCUBE1 and CTRP5 for poor prognosis in patients with pulmonary heart disease. Results: The serum levels of SCUBE1 and CTRP5 in the pulmonary heart disease group were obviously higher than those in the control group(P<0.05); the serum levels of SCUBE1 and CTRP5 in the compensated group were obviously lower than those in the decompensated group(P<0.05); the proportion of smoking history, and the levels of serum SCUBE1 and CTRP5 in the poor prognosis group were obviously higher than those in the good prognosis group(P<0.05); smoking history, serum SCUBE1 and CTRP5 were risk factors for poor prognosis in patients with pulmonary heart disease(P<0.05); the prediction of combined serum SCUBE1 and CTRP5 for poor prognosis in patients with pulmonary heart disease was obviously more effective than the two alone prediction(ZSCUBE1-combined prediction=3.765,P<0.001;ZCTRP5-combined prediction=2.067,P=0.039). Conclusion: The levels of serum SCUBE1 and CTRP5 in patients with pulmonary heart disease are closely related to disease progression and prognosis, and the combination of the two has high predictive value for patient prognosis.
参考文献：

[1] 田聪, 罗艳丽, 刘锐等.肺心病患者Gal-3、fetuin-A表达及与病情相关性分析[J].标记免疫分析与临床, 2023, 30(7):1159-1163.
[2] 程迪, 吕镗烽.肺癌患者免疫检查点抑制剂相关肺炎的危险因素及临床特点[J].东南大学学报(医学版), 2024, 43(4):516-522.
[3] 崔玉清.酚妥拉明联合利尿剂治疗肺心病的临床疗效[J].当代临床医刊, 2023, 36(3):91-92.
[4] 宋培培, 张伟伟, 常慧, 等.血清miR-21、NT-proBNP、HSP27联合检测对慢性肺源性心脏病患者的临床诊疗价值[J].检验医学与临床, 2023, 20(11):1637-1640.
[5] TOPRAK K, KAPLANGORAY M, PALICE A, et al.SCUBE1 is associated with thrombotic complications, disease severity, and in-hospital mortality in COVID-19 patients[J].Thromb Res, 2022, 220(1):100-106.
[6] LIAO W J, WU M Y, PENG C C, et al.Epidermal growth factor-like repeats of SCUBE1 derived from platelets are critical for thrombus formation[J].Cardiovasc Res, 2020, 116(1):193-201.
[7] LIU Y, WEI C, DING Z, et al.Role of serum C1q/TNF-related protein family levels in patients with acute coronary syndrome[J].Front Cardiovasc Med, 2022, 9(1):967918-967929.
[8] 钟春燕.慢性心力衰竭患者血清IL-1β、TNF-α、CTRP5的变化及临床意义[J].心血管病防治知识, 2023, 13(5):21-24.
[9] ZHANG Y, LIU C, LIU J, et al.Implications of C1q/TNF-related protein superfamily in patients with coronary artery disease[J].Sci Rep, 2020, 10(1):878-889.
[10] SI Y, FAN W, SUN L.A review of the relationship between CTRP family and coronary artery disease[J].Curr Atheroscler Rep, 2020, 22(6):22-29.
[11] 中华医学会, 中华医学杂志社, 中华医学会全科医学分会, 等.慢性肺源性心脏病基层诊疗指南(2018 年)[J].中华全科医师杂志, 2018, 17(12):959-965.
[12] 陈雅丽, 闫佩佩, 白雪洋, 等.酚妥拉明、多巴胺及卡托普利三联疗法治疗肺源性心脏病的效果及其对患者心功能的影响[J].临床医学工程, 2022, 29(4):471-472.
[13] 唐宇乐, 胡业焕, 李丹妮, 等.丹参注射液联合环磷腺苷葡胺治疗肺源性心脏病的临床效果[J].临床合理用药杂志, 2022, 15(20):52-54.
[14] 秦璐璐, 蔡红, 施爱花.血清高迁移率族蛋白1和克拉拉细胞分泌蛋白及血管内皮生长因子检测对肺源性心脏病呼吸衰竭患者预后的预测价值[J].中国心血管病研究, 2022, 20(12):1114-1119.
[15] 滕慧芳, 秦仕虹, 符代炎.肺动脉内皮细胞炎症反应在低氧性肺动脉高压中的作用研究进展[J].实用心脑肺血管病杂志, 2023, 31(7):33-39.
[16] 林晓伟, 邓明尧, 吉晓理, 等.血清SCUBE1、Endocan水平与急性ST段抬高型心肌梗死患者PCI术后冠状动脉无复流的关系[J].中国动脉硬化杂志, 2023, 31(1):56-62.
[17] 高运霞, 高艳玲, 高超, 等.血清SCUBE1对老年缺血性心力衰竭患者的预后评估研究[J].中国循证心血管医学杂志, 2023, 15(6):662-666.
[18] 李圳, 徐志红, 胡家安.急性肺血栓栓塞症诊断相关生物标志物研究进展[J].内科理论与实践, 2021, 16(1):60-63.
[19] 杨宏秀, 袁宝军, 刘丽, 等.血清CTRP1、CTRP5和CTRP1/CTRP5水平与不稳定型心绞痛的关系[J].天津医药, 2023, 51(3):307-310.
[20] 杨敏炜, 王利军, 王龙.社区获得性肺炎患者血清CTRP5水平及与炎症细胞因子的关系[J].中国现代医学杂志, 2020, 30(10):112-116.
[21] 龙借帆, 李翠, 高元标, 等.联合检测血清SIRT1和CTRP5水平对慢性阻塞性肺疾病急性加重期患者预后的预测价值研究[J].现代检验医学杂志, 2022, 37(3):162-166.
[22] LI C, CHEN J W, LIU Z H, et al.CTRP5 promotes transcytosis and oxidative modification of low-density lipoprotein and the development of atherosclerosis[J].Atherosclerosis, 2018, 278(1):197-209.
服务与反馈：
【文章下载】【发表评论】【查看评论】【加入收藏】
提示：您还未登录，请登录！点此登录
您是第 489684 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话：025-83272481 83272483
电子邮件： bjb@pub.seu.edu.cn

本系统由北京博渊星辰网络科技有限公司设计开发 技术支持电话：010-63361626

苏ICP备09058364